To evaluate retreatment indications/morphologic responses to ranibizumab monotherapy and combination with verteporfin photodynamic therapy (PDT).
A total of 40 patients received 3 monthly intravitreal ranibizumab 0.3 mg injections combined with either PDT or sham PDT at baseline (1:1) followed by as-needed ranibizumab based on predetermined vision/anatomical criteria.
Retreatment criteria were visual acuity (VA) loss (59%/58%), central retinal thickness (CRT) increase (27%/26%), or both (14%/16%). One month before retreatment, intraretinal cysts (IRC) were present in 84%/74%, subretinal fluid (SRF) in 70%/63%, and at least one of them in 84%/89% of eyes. A significant decrease in mean leakage area, IRC, and SRF as well as a reduction in presence of hemorrhages and hard exudates occurred in both treatment groups at 12 months (compared to baseline).
Retreatment indications were mostly based on VA loss, probably due to the quantitative optical coherence tomography criterion. Intraretinal cysts and SRF were earlier predictors for recurring choroidal neovascularization (CNV) activity than CRT/VA changes. Both treatment strategies were equally potent in reducing CNV activity.
Eur J Ophthalmol 2017; 27(4): 470 - 475
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsKatja Hatz, Ulrike Schneider, Bernhard Henrich, Beatrice Braun, Stefan Sacu, Christian Prünte
- • Accepted on 15/09/2016
- • Available online on 13/10/2016
- • Published in print on 26/06/2017
This article is available as full text PDF.
- Hatz, Katja [PubMed] [Google Scholar] 1, 2, 3
- Schneider, Ulrike [PubMed] [Google Scholar] 3, 4
- Henrich, Bernhard [PubMed] [Google Scholar] 4
- Braun, Beatrice [PubMed] [Google Scholar] 4
- Sacu, Stefan [PubMed] [Google Scholar] 5
- Prünte, Christian [PubMed] [Google Scholar] 1, 2, 3, 4, 5, * Corresponding Author (email@example.com)
Vista Klinik, Binningen - Switzerland
Department of Ophthalmology, Kantonsspital Liestal, Liestal - Switzerland
University of Basel, Basel - Switzerland
University Eye Hospital Basel, Basel - Switzerland
Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna - Austria